OSI-211 (Liposomal Lurtotecan)

DRUG2 trials

Sponsors

Astellas Pharma Inc

Conditions

Carcinoma, Small CellOvarian NeoplasmsSCLC

Phase 2

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

CompletedNCT00046800

Astellas Pharma IncOvarian Neoplasms

Start: 2002-09-30End: 2003-03-31Target: 80Updated: 2011-10-20

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

CompletedNCT00046787

Astellas Pharma IncCarcinoma, Small Cell, SCLC

Start: 2002-09-30End: 2003-02-28Target: 47Updated: 2011-10-20